Visby Medical™ Secures Landmark De Novo FDA Approval for OTC STI Test Read more
Visby Medical
How to Buy
Visby Medical
How to Buy

Our Team

We’re all about connecting the dots. From problem-solving to discovering new solutions, we pride ourselves on assembling a team that values curiosity, determination, and creative, empathic thinking.
Visby Leadership

Adam de la Zerda, PhD

Founder & CEO

Gary Schoolnik, MD

Chief Medical Officer

Tony Allen, SVP of Manufacturing & Operations

Tony Allen

SVP of Manufacturing & Operations

Beth Lingenfelter

SVP of Quality, Regulatory, and Clinical Affairs

Shaunak Roy, PhD

SVP of Research & Development

Bill Meyer

VP of Finance

Dylan Taylor, VP of Legal Affairs

Dylan Taylor

VP of Legal Affairs

Chris Weaver, VP of Commercial Operations - Visby Medical

Chris Weaver

VP of Commercial Operations

Board Members

Adam de la Zerda, PhD

Founder & CEO

Everett Cunningham

Everett Cunningham

Illumina, Inc

Ittai Harel

Pitango Ventures

Shlomo Melmed, MD

Cedars-Sinai Medical Center

Eric Moessinger

ND Captial

Amit Shah

Artiman Ventures

Board Observers

Ryan Panchadsaram

Kleiner Perkins

Ashish Puri

Lightrock

Don Lacey

Ping An Global Voyager

Advisor

David Shaw

Black Point Group

Scientific Advisory Board

Richard Whitley, MD

Chair of Scientific Advisory Board, University of Alabama at Birmingham

Angela Caliendo, MD, PhD

Brown University

Edward Hook, MD

University of Alabama at Birmingham

David A. Relman, MD

Stanford University

In memory of

Greg Loney

Co-founder & Former CTO

Jerome Behar

Nissim Capital, Former Board Member

Share Our Vision

At Visby, everyone’s voices and ideas are valued, because we know that our sum is only greater when each teammate’s whole self is brought to the table. If you’re ready to help usher in the future of diagnostics, check out our open roles today.
View Open Positions

Headquarters

3010 North First Street
San Jose, CA 95134

Connect
Linkedin
©2025 Visby Medical, Inc. All rights reserved. Visby Medical and the Visby Medical logo are registered trademarks of Visby Medical, Inc.
Adam de la Zerda, PhD
Founder & CEO
Dr. Adam de la Zerda is the Founder and CEO of Visby Medical. Dr. de la Zerda is also an Associate Professor at Stanford University School of Medicine. In 2012, he became the youngest tenure track faculty at Stanford Medical School. He has experience in basic and translational research in molecular diagnostics, with biomedical engineering training during his PhD studies at Stanford University, chemistry and biochemistry postdoctoral training at University of California at Berkeley, and electrical engineering, computer science and physics training in his undergraduate studies at the Technion – Israel Institute of Technology. He has received over 20 honors and awards including Forbes Magazine 30-under-30 in Science and Healthcare in 2013 and 2014, Chan-Zuckerberg Investigator from Facebook Founder and CEO Mark Zuckerberg, DP5 Early Independence Award from the Director of the NIH, and he recently gave a popular TED Talk.
Gary Schoolnik, MD
Chief Medical Officer

Dr. Schoolnik is Chief Medical Officer, Visby Medical. He is also Professor of Medicine (emeritus), Stanford Medical School, Attending Physician in Internal Medicine and Infectious Diseases at Stanford University Hospital and Associate Director of Stanford’s Institute for Immunology, Transplantation and Infection.

Dr. Schoolnik received his M.D. degree and infectious diseases subspecialty training at the University of Washington in Seattle, served as medical intern, resident and chief resident at Harvard’s Massachusetts General Hospital in Boston and he was a research associate and associate physician at the Rockefeller University in Manhattan. While on the Stanford Medical School faculty he served as Chief of the Division of Infectious Diseases and Geographic Medicine. National service included his appointment to the Advisory Council of the National Institutes of Allergy and Infectious Diseases of the NIH and his role as chair of the NIH Trans-Institute Committee on the Human Microbiome and co-chair of the NIH Blue Ribbon Committee on Bioterrorism. International consultative activities include the Board of Scientific Counselors of Fudan University in Shanghai. 

He was founding editor of the journal Molecular Microbiology and Associate Editor of the Journal of Clinical Investigation. His academic research focuses on the molecular, genetic and genomic aspects of infectious agents and on the development of new drugs, vaccines and diagnostics. Gary has 6 issued patents.

Tony Allen, SVP of Manufacturing & Operations

Tony Allen

SVP of Manufacturing and Operations

Steering Visby Medical’s operations with a steadfast commitment to excellence, Tony’s role as Senior VP Operations is focused on strategic manufacturing process improvement and operational excellence. Previously, at Thermo Fisher Scientific, Lucira Health and Ortho Clinical Diagnostics , Tony championed initiatives that amplified operational performance, translating into tangible quality enhancements. With a proven track record in leading continuous improvement efforts, Tony’s expertise in operations management is pivotal in advancing Visby Medical’s position in the competitive landscape of medical device technology.

Beth Lingenfelter
SVP of Quality, Regulatory, and Clinical Affairs
Beth has over 25 years of experience in leadership roles in Quality, Regulatory, Clinical, and Scientific Affairs for molecular in vitro diagnostic companies. She has extensive experience working in highly entrepreneurial environments and has been responsible for starting several new departments for companies that are in the process of establishing businesses in the IVD space. This includes implementation of a robust quality system at Myriad Genetics (a CLIA and New York State certified laboratory specializing in resequencing to determine cancer risk) and starting the Quality, Regulatory and Clinical Affairs Departments at Idaho Technology (now known as BioFire Diagnostics) a highly successful IVD and biotechnology company. While leading Regulatory and Clinical Affairs at BioFire, we obtained FDA clearances and CE marking for 3 molecular syndromic infectious disease tests with review times that were consistently less than the 90-day review period. Beth holds a MS in clinical laboratory science from the University of Illinois at Chicago and enjoys being outside hiking, biking, skiing or playing tennis.
Shaunak Roy, PhD
SVP of Research & Development
Dr. Roy has 16 years experience developing complex biomolecular systems in the Life Science and In Vitro Diagnostics industries. He was the eighth employee hired at Geneweave Biosciences, where he eventually went on to become the head of engineering and develop an instrument and cartridge platform for the detection of infectious disease. Geneweave was acquired by Roche Molecular Systems in 2015. Prior to Geneweave, Shaunak was a Senior Process Engineer at Complete Genomics, where he worked on what was at the time, the world’s fastest DNA sequencer. Complete Genomics went IPO in 2010 and was acquired by BGI in 2012. At Visby, Shaunak leads our Research and Development organization and is responsible for all aspects of product development, from high level concept and feasibility work to launch of new assays and platforms. He holds a BS in Chemical Engineering from Northwestern University and a PhD in chemical engineering from Stanford University. He is an author on four published papers and twenty two issued patents.
Bill Meyer
VP of Finance
Mr. Meyer has over 30 years of leadership experience in Silicon Valley finance and accounting. He’s helped several public and late-stage private companies develop strategic plans and implement tactical growth and restructuring plans. He’s led multiple public offerings and buyside and sellside transactions of up to $600 million. Prior to joining Visby, Bill provided strategic and tactical financial consulting services to leading Silicon Valley companies in various industries, including medical diagnostics. Previously, he held Chief Financial Officer and other senior finance roles at Bell Microproducts, Broadvision, inSilicon, Phoenix Technologies and Arthur Andersen. He received his BS degree from California State University, Sacramento, and is a CPA in the state of California (inactive).
Dylan Taylor, VP of Legal Affairs

Dylan Taylor

VP of Legal Affairs

Dylan is a licensed attorney with more than a decade of leadership experience in the medical device industry providing in-house legal counsel
and strategic advice to executive management teams and their board of directors. Following his experience as a civil defense trial lawyer, Dylan
joined Quidel Corporation in 2013, and took on leadership responsibilities in all functions of the legal department that supported a rapidly growing
business in the point-of-care IVD market with annual revenues that expanded from $180m to over $3.2b at its peak.

As part of his road scope of responsibilities at Quidel, Dylan managed all litigation matters, including successfully leading the defense against Beckman’s antitrust lawsuit in a decision that was upheld by the California Supreme Court, and led to the sale of the underlying business at issue for approximately $700m. With respect to his efforts on the revenue-generating side of the business, Dylan was the lead attorney supporting the global commercial teams during his tenure and was instrumental in the
commercial launch of Quidel’s first-to-market COVID-19 rapid antigen test, as well as Quidel’s first ever over-the-counter consumer products. Following
the company’s acquisition of Ortho Clinical Diagnostics, Inc., he was added to the North America Leadership Team to provide strategic guidance to
QuidelOrtho’s senior commercial executives.

Dylan has a background both in playing and coaching competitive sports throughout his life, and continues to thrive in competitive environments
with a focus on team building and winning. He received his Bachelor’s degree from the University of California, Berkeley, and his law degree from the University of San Diego School of Law.

Chris Weaver, VP of Commercial Operations - Visby Medical

Chris Weaver

VP of Commercial Operations

Chris Weaver brings over 25 years of leadership experience in the Point-of-Care diagnostics industry to his role as Vice President of Commercial Operations at Visby Medical. Throughout his  career, Chris has held senior roles at Siemens, Alere, and Cepheid, where he was instrumental in driving commercial strategy, fostering key distribution partnerships, and accelerating market growth in the Point-of-Care space. At Visby Medical, Chris leads efforts to drive both commercial success and operational excellence. He is deeply involved in expanding market reach, optimizing revenue streams, and crafting strategic go-to-market plans that position Visby’s innovative diagnostic solutions at the forefront of healthcare. His focus on building strong customer relationships ensures that Visby continues to deliver transformative diagnostic technologies to healthcare providers. Chris is passionate about revolutionizing healthcare through cutting-edge diagnostics and is committed to amplifying Visby’s contribution to improving global health outcomes.